Check out the new article by long-time TOBI faculty, Dr. Gerard Malanga, published in Biologic Orthopedic Journal.
By the year 2040, it is estimated that 25% of adults in the US will be diagnosed with osteoarthritis by a physician. Osteoarthritis, considered as a progessive joint disorder due to “wear and tear,” has been described by researchers to involve a complex dynamic of pro-inflammatory mediators leading to an increase of enzymes that degrade soft-tissue supporting the joint. This article looks at the chemical composition of Adipose-derived MSCs, and the use of anti-inflammatory properties there within, to combat the progression of tissue degradation in knee osteoarthritis. Micro-fragmented Adipose tissue versus Enzyme-Processed Adipose tissue is further evaluated with respect to the biochemical profile of Adipose-derived MSCs for clinical efficacy in the treatment of knee osteoarthritis. After injection, a variety of bioactive molecules and cell markers initiate and promote cell-signaling mechanisms to transport cellular proteins and genetic information. This article provides a table summary of the biochemical profile of AD-MSCs.
In conclusion, a substantial body of research suggests that AD-MSC therapy has a well-documented immune-modulating role in delaying or preventing the onset of end-stage knee osteoarthritis. Congratulations to TOBI faculty Dr. Malanga for his contribution to this study published in the Biologic Orthopedic Journal. Download the full article here https://www.biologicortho.com/index.php/BiologicOrtho/article/view/7